Industrialization of cell therapy manufacturing: from artisanal process to scalable medicine
Cell and Gene Therapy Insights · 28.05.2026 · 12 (4) · 459–468
DOI: 10.18609/cgti.2026.050 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell and Gene Therapy Insights, online erschienen am 28.05.2026. Verfasst von Sapna Tandon. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
This perspective article focuses specifically on autologous and engineered cell therapies, including CAR‑T cell, tumor‑infiltrating lymphocyte (TIL), and stem cell therapies, where the patient’s own cells constitute the therapeutic product. While gene therapies using viral vectors (e.g., AAV, lentiviral) share some manufacturing challenges, they are addressed here only as far as they are integral to cell engineering workflows. The central argument is that industrialization – encompassing scalable manufacturing, advanced analytics, quality systems, and regulatory innovation – is no longer aspirational but operationally necessary to achieve widespread, affordable patient access.
Zitieren
APA
Tandon, S. (2026). Industrialization of cell therapy manufacturing: from artisanal process to scalable medicine. Cell and Gene Therapy Insights, 12(4), 459–468. https://doi.org/10.18609/cgti.2026.050
Vancouver
Tandon S. Industrialization of cell therapy manufacturing: from artisanal process to scalable medicine. Cell and Gene Therapy Insights. 2026;12(4):459–468. doi:10.18609/cgti.2026.050
BibTeX
@article{Tandon2026,
author = {Tandon, Sapna},
title = {Industrialization of cell therapy manufacturing: from artisanal process to scalable medicine},
journal = {Cell and Gene Therapy Insights},
year = {2026},
volume = {12},
number = {4},
pages = {459–468},
doi = {10.18609/cgti.2026.050}
}
EUVIMED